Individualized 5-FU Treatment Study Planned for Patients with Metastatic Colorectal Cancer

Share this content:

(ChemotherapyAdvisor) – A single-arm study of patients with metastatic colorectal cancer will determine whether pharmacokinetic-guided 5-fluorouracil (5-FU) regimens can provide steady dose levels while reducing toxicities such as grade 3/4 mucositis and diarrhea, Saladax Biomedical, Inc., and the Central European Society for Anticancer Drug Research (CESAR) announced today.

The collaborative trial will determine whether 5-FU target blood levels can be maintained through six courses of treatment by optimizing the dose administered to individual patients at each infusion using the Saladax Biomedical My5-FU automated immunoassay for personalized dose adjustment, according to Saladax Biomedical, Bethlehem, PA, and CESAR, Vienna, Austria.

Planned enrollment at the four study sites in Germany is 80 patients and study duration is anticipated to be one year.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs